Pharma Industry News Update: 25 April 2017
IoT Impact on Outcomes and Adherence While attending an eyeforpharma Philadelphia conference, Pharmaguy interviewed Jeff Usewick, Director for Healthcare Business Development at SoftServe, about how the drug industry should focus on using Internet of Things technology to improve health outcomes. Better adherence and profits will then follow.
Apple Watch Nerds Working on Prickless Glucose Monitoring Sensor
[From www.cnbc.com] Apple has hired a small team of biomedical engineers to work at a nondescript office in Palo Alto, miles from corporate headquarters. They are part of a super secret initiative, initially envisioned by the late Apple co-founder Steve Jobs, to develop sensors that can non-invasively and continuously monitor blood sugar levels to better treat diabetes, according to three people familiar with the matter.
Such a breakthrough would be a “holy grail” for life sciences. Many life sciences companies have tried and failed, as it’s highly challenging to track glucose levels accurately without piercing the skin.
The initiative is far enough along that Apple has been conducting feasibility trials at clinical sites across the Bay Area and has hired consultants to help it figure out the regulatory pathways, the people said.
Further Reading:
- Will Silicon Valley Startups & Empowered Patients Replace #BigPharma?
- Scientists Skeptical of Google’s Verily Life Sciences Technology
Digital Disrupters Hope to Take Big Pharma “Beyond the Pill”
[From www.ft.com] Investors are starting to bet heavily on the potential of technological innovation to transform the way healthcare is delivered. According to Rock Health, a venture fund dedicated to digital health, a total of $4.2bn was invested in the sector last year, with companies in the analytics and big data category attracting $341m over 22 deals, more than doubled from 2015.
However the pharma industry will have to grapple with its own entrenched culture if it is to take advantage of the expansion in digital technologies.
Further Reading:
- Pharma Investing Across Digital Health, Biotech, And Medical Devices
- Will #Pharma Morph Into a Consumer-focused mHealth App Developer Business?
- Why Silicon Valley Keeps Getting Biotechnology Wrong
Bayer’s New Grants4Apps DealMaker for Mature Companies
[From www.grants4apps.com]
Calling all mature teams, startups and companies that have a solution ready to go! Our new Dealmaker is all about quality face time between you and our experts for one full day.
- Close a potential project deal with Bayer
- Attend the One-day matchmaking event
- Pitch your startup and discuss possible projects
If there is a match, we will invite you to Berlin to pitch your solution, discuss collaboration options and close a deal. Travel expenses are on us! Find out, if there is a mutual interest to start a bigger journey together!
We have put together specific challenges in which we are especially interested in solving with you!
Challenges:
- Artificial Intelligence
- Data Analysis
- IT
- Clinical Trials
- Nephrology
- Women’s Health
- Pulmonology
- Ophthalmology
Why Silicon Valley Keeps Getting Biotechnology Wrong
